Copiktra™ was approved in late 2018
KINGMAN – The Kingman Regional Medical (KRMC) Center Cancer Center is the first provider in the nation to use a newly-approved therapy for cancers of the blood.
The U.S. Food and Drug Administration (FDA) approved Copiktra™ for clinical use in September, 2018.
Copiktra™ is a prescription capsule taken by mouth. It is used to treat adults who have not responded or stopped responding to two prior therapies. Copiktra™ is approved for patients with:
· Chronic Lymphocytic Leukemia (CLL)
· Small Lymphocytic Lymphoma (SLL)
· Follicular Lymphoma
KRMC Medical Oncologist Dr. Edgardo Rivera prescribed Copiktra™ to treat a patient with follicular lymphoma last December. The patient is still receiving the treatment and responding well, said Dr. Rivera.
The KRMC Cancer Center treats patients with all types of cancer, including complex and late-stage cases. As the largest cancer treatment provider in Northwest Arizona, the KRMC Cancer Center strives to stay up-to-date on the latest advances in cancer care.
